PAREXEL LAUNCHES IMPACT EXPRESS CLINICAL TRIAL MANAGEMENT SYSTEM

BOSTON, December 1, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today introduced IMPACT^® Express Clinical Trial Management System (CTMS). IMPACT Express provides a quick-to-implement, cost-effective clinical trial management solution to simplify clinical trial management and monitoring for small to mid-sized biopharmaceutical companies.

Clinical trials are the most expensive component of the drug development process. Use of a single, unified clinical trial management system plays a vital role in helping biopharmaceutical companies’ plan, track, record, and oversee the complex array of administrative, financial, site-related, and other activities that are critical for the efficient monitoring and management of clinical trials.

“PAREXEL developed IMPACT Express for biopharmaceutical and biotech companies in need of a scalable, rapid-to-deploy and cost-effective CTMS option to intelligently manage the complexities of clinical trials,” said Patrick Nadolny, Vice President of Product Management, Data and Analytics Services, PAREXEL Informatics.  “By applying a process-driven approach to trial management and monitoring, biopharma companies will be better able to save time – and money – while simplifying their drug development journey.” 

IMPACT Express draws on PAREXEL Informatics’ commitment to operational excellence and 20+ years of investment in CTMS innovations and process improvements coupled with the feedback and hands-on experiences of users around the world.  Biopharmaceutical, medical device and research organizations of all sizes have used PAREXEL’s CTMS solutions to manage more than 25,000 trials.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,620 employees in the first quarter.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL, PAREXEL Informatics, and IMPACT are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains “forward-looking” statements regarding future results and events.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,”  “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.